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Abstract
Background: Although the etiology of idiopathic pulmonary fibrosis (IPF) remains perplexing, adaptive immune activation is
evident among many afflicted patients. Repeated cycles of antigen-induced proliferation cause T-cells to lose surface
expression of CD28, and we hypothesized this process might also occur in IPF.
Methodology/Principal Findings: Peripheral blood CD4 T-cells from 89 IPF patients were analyzed by flow cytometry and
cytokine multiplex assays, and correlated with clinical events. In comparison to autologous CD4+CD28+cells, the unusual
CD4+CD28null lymphocytes seen in many IPF patients had discordant expressions of activation markers, more frequently
produced cytotoxic mediators perforin (2.460.8% vs. 60.067.4%, p,0.0001) and granzyme B (4.562.8% vs.74.966.5%,
p,0.0001), produced greater amounts of many pro-inflammatory cytokines, and less frequently expressed the regulatory T-
cell marker FoxP3 (12.961.1% vs. 3.360.6% p,0.0001). Infiltration of CD4+CD28null T-cells in IPF lungs was confirmed by
confocal microscopy. Interval changes of CD28 expression among subjects who had replicate studies were correlated with
conterminous changes of their forced vital capacities (rs= 0.49, p = 0.012). Most importantly, one-year freedom from major
adverse clinical events (either death or lung transplantation) was 5666% among 78 IPF patients with CD4+CD28+/
CD4total$82%, compared to 969% among those with more extensive CD28 down-regulation (CD4
+CD28+/CD4total,82%)
(p = 0.0004). The odds ratio for major adverse events among those with the most extensive CD28 down-regulation was 13.0,
with 95% confidence intervals 1.6-111.1.
Conclusions/Significance: Marked down-regulation of CD28 on circulating CD4 T-cells, a result of repeated antigen-driven
proliferations, is associated with poor outcomes in IPF patients. The CD4+CD28null cells of these patients have potentially
enhanced pathogenic characteristics, including increased productions of cytotoxic mediators and pro-inflammatory
cytokines. These findings show proliferative T-cell responses to antigen(s) resulting in CD28 down-regulation are associated
with progression and manifestations of IPF, and suggest assays of circulating CD4 T-cells may identify patients at greatest
risk for clinical deterioration.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic fibroprolifera-
tive lung disease that afflicts ,40,000 patients in the U.S. each
year [1]. IPF typically manifests with inexorable pulmonary
restriction and hypoxemia, resulting in progressive exercise
limitation and dyspnea. The disease has a grim prognosis, with a
median survival of ,3 years after diagnosis, although courses can
be highly variable. No medical treatments have yet been shown to
alter the natural history of this disease [1,2].
The etiology of IPF is enigmatic. Although not widely
considered to be an immunologic disorder [2], several studies
have shown that adaptive immune responses are often active in
IPF patients, as evidenced by the frequent presence of IgG
autoantibodies, increased productions of lymphocyte-derived
inflammatory mediators, and abnormal extents of T-cell activation
and clonal proliferations [3–13]. Activated CD4 T-cells may also
infiltrate into IPF lungs prior to development of symptoms [14],
and pro-inflammatory dendritic cells accumulate in the pulmonary
parenchyma of advanced cases [15]. FoxP3+ regulatory T-cells
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(Treg), widely regarded as having important roles in dampening
adaptive immune responses against antigens [16], are diminished
in both the circulation and broncholavolar lavage returns of IPF
patients [17]. More directly compelling, a protein(s) uniquely
present in IPF lungs induces proliferation of autologous CD4 T-
cells from these patients [13].
We hypothesized that if IPF progression does indeed have an
important adaptive immune component, we may be able to find
associations between phenotypic alterations of circulating T-cells and
clinical manifestations of the disease. We focused attention on CD4
T-lymphocytes of the patients, given the singular role of these cells in
orchestrating adaptive immune responses [18], and their responsive-
ness to IPF-associated intrapulmonary antigen(s) [13]. Nearly all CD4
T-cells of healthy, normal individuals express CD28, a co-stimulatory
molecule that provides a ‘‘second signal’’ for activation of naı¨ve CD4
lymphocytes. However, human T-cells that have undergone repeated
cycles of antigen-driven proliferation develop a series of phenotypic
and functional changes, including the disappearance of cell-surface
CD28. Hence, finding significant proportions of circulating
CD4+CD28null cells is a de facto marker denoting the presence of a
chronic adaptive immune response [19–34].
Accordingly, we characterized CD28 expression on the
circulating CD4 T-cells of a well-defined IPF cohort, and
correlated results of the immunologic assays with clinical features
of these patients. We found abnormally large proportions of
peripheral CD4 T-cells in some IPF patients lack CD28
expression, and these CD4+CD28null cells also have unusual,
and potentially pathogenic, functional alterations. Most impor-
tantly, the presence of significant CD28 down-regulation identified
IPF subjects who had particularly poor clinical outcomes,
analogous to observations in other patient populations with
chronic immunologic diseases [20–23,32–34].
Results
CD4 T-Cell Expression of CD28 among IPF Patients
Eighty-nine (89) IPF subjects had one or more assays of their
peripheral blood CD4 T-cells. Unless otherwise specified, only
results of their latest determinations are described. Clinical
observation periods following their last experimental T-cell assays
exceeded 12 months in all subjects who survived and/or did not
have lung transplantation. The proportion of total circulating CD4
T-cells that co-expressed CD28 were determined for each subject,
and these values are defined here as CD28% [20]. CD28 down-
regulation was striking in some IPF patients (Figure 1A), and
nineteen (21%) of these subjects had CD28% ,90. Ages of the 32
normal, healthy controls (67.961.1 years old) were comparable to
those of the IPF subjects (p = N.S.). None of the normal controls
had CD28% ,90, and their aggregate values of this parameter
(97.960.4) were significantly greater than those of the IPF subjects
(Figure 1A).
Phenotypic Features of IPF CD4+CD28null Cells
We performed a series of assays (Figure 1B) to ascertain if the
CD4+CD28null cells of IPF patients exhibited unusual phenotype
characteristics, as has been observed elsewhere in comparable cells
from patients with chronic adaptive immune disorders [19–34].
Because the CD4+CD28null lymphocytes are daughter progeny
of repetitive, antigen-driven T-cell replication cycles
[19,20,25,27,30,31], we anticipated these cells would be highly
activated. A greater proportion of the IPF CD4+CD28null did
express major histocompatibility antigen (MHC) Class II (HLA-
DR) than the corresponding autologous CD4+CD28+ cells.
However, IPF CD4+CD28null cells paradoxically expressed less
CD25 than autologous CD4+CD28+ cells, and this discordant
expression of activation markers has also been previously reported
in cells derived from another patient population [20]. There was
no apparent correlation between CD4 values (as percentages of
total peripheral blood mononuclear cells [PBMNC]) and CD28%
(rs = 0.16, p = N.S.)
Selected intracellular factors and mediators with potential
clinical relevance were also evaluated here. The lesser expression
of CD25 by IPF CD4+CD28null cells prompted us to measure
FoxP3, and this transcription factor and marker for regulatory T-
cell (Treg) function was present in significantly fewer of these cells
than among corresponding CD4+CD28+ lymphocytes (Figure 1B).
Pulmonary epithelial cell death may be an important pathologic
process in IPF [35], leading us to also evaluate potential cytotoxic
functions of the CD4 T-cell subpopulations. Cell surface
expression of FasL was at or below the detection threshold for
flow cytometry in both CD4 subpopulations (data not shown), but
the IPF CD4+CD28null lymphocytes frequently produced perforin
and granzyme B, in striking contrast to autologous CD4+CD28+
cells (Figure 1B).
CD4+CD28null T-Cells of IPF Patients Produce Pro-
Inflammatory Cytokines
CD4+CD28null T-cells from patients with autoimmune diseases or
other chronic immunologic disorders have abnormal productions of
various cytokines that may have potential importance in disease
pathogenesis [19,20,24]. Differential cytokine productions of
autologous CD4+CD28+ and CD4+CD28null cells from these IPF
patients were also evident in multiplex analyses (Figure 2), and the
mediator elaboration profiles of these lymphocytes were similar to
those of comparable cell subpopulations isolated from transplanta-
tion recipients [20]. CD4+CD28null cells generally produced much
greater amounts of pro-inflammatory and TH1 mediators under
basal conditions, and in many cases these productions were
strikingly increased by T-cell antigen receptor (TCR) cross-linking
Figure 1. Characteristics of CD4 T-cell subpopulations in IPF
patients. A: The proportions of circulating CD4 T-cells that also
expressed CD28 (CD28%) were reduced in many IPF patients. The
horizontal line denotes the population means. B: In contrast to
autologous CD4+CD28+ cells, the CD4+CD28null T-cells of IPF patients
more often express major histocompatibility antigen (MHC) Class II (DR),
but less frequently express CD25. CD4+CD28null T-cells of IPF patients
less frequently produce transcription factor FoxP3 (a putative marker of
regulatory T-cells), but much more frequently produce cytotoxic
mediators granzyme B (GB) and perforin (Perf). For each measure
n = 24, and p values for all intergroup comparisons (CD4+CD28+ vrs.
CD4+CD28null cells) are ,0.0001.
doi:10.1371/journal.pone.0008959.g001
CD4+CD28null T-Cells in IPF
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with anti-CD3 antibody (thereby replicating effects of T-cell-antigen
engagements) (Figure 2). Conversely, and with the exception of IL-4,
productions of TH2 cytokines, notably including putatively immu-
nosuppressive IL-10, were reduced among the CD4+CD28null cells
in comparisons to autologous CD4+CD28+cells.
CD4+CD28null Lymphocytes Isolated from IPF Patients Are
Capable of Further Proliferation
Several studies of CD4+CD28null cell lines derived by
extensive ex vivo propagation suggest these lymphocytes are
replicatively sencescent [19]. Nevertheless, we have previously
shown that freshly isolated CD4+CD28null lymphocytes from
lung transplant recipients are able to proliferate with TCR cross-
linking [20], raising the possibility that the reported inability of
CD4+CD28null cell lines to divide is a consequence of their
protracted in vitro propagation. In order to further evaluate
this hypothesis, we measured proliferations of segregated
CD4+CD28+ and CD4+CD28null lymphocytes from IPF subjects
after stimulation that mimics T-cell engagement with antigen-
MHC complexes (e.g., plate bound anti-CD3 monoclonal
antibodies).
As was seen in previous study of cells isolated from allograft
recipients [20], proliferation of CD4+CD28null T-cells from the
IPF patients was near identical to that of autologous CD4+CD28+
cells (Figure 3).
CD28 Expression Is Associated with Changes of
Pulmonary Function in IPF Patients
Pulmonary function tests (PFT) were ordered by physicians
caring for these patients on the basis of clinical indications, while
Figure 2. Cytokine elaborations by autologous CD4 subpopulations of IPF patients. Initial (left) data point in each series represents
control unstimulated (basal) condition, while second (right) data point delineates productions of cells after stimulation with plate bound anti-CD3
antibody. These paired specimens (control and stimulated) are also connected by lines. CD4+CD28null cells from IPF patients (open circles with paired
specimens connected by dashed lines) tend to elaborate greater amounts of pro-inflammatory and TH1 cytokines (top two rows), whereas
CD4+CD28+ cells (open squares with paired specimens connected by solid lines) have an apparent TH2 bias, with the exception of IL-4 production
(bottom row) (n = 6 randomly-selected specimens in each measure).
doi:10.1371/journal.pone.0008959.g002
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blinded to the experimental immunologic assays. Seventy-one (71)
subjects had CD4 T-cell assays concurrent with measures of forced
vital capacity (FVC), and 57 of these also had determinations of
diffusing capacity for carbon monoxide (DLCO). CD28% values
modestly, but significantly correlated with concordant DLCO of
the subjects (rs = 0.34, p = 0.01). The cross-sectional relationships
between CD28% values and other PFT parameters were not
significant (data not shown).
Although single, essentially random measures of CD28% had
only limited correlation with concurrent PFT values, these
particular T-cell assays have been shown elsewhere to be
predictive for subsequent changes of physiologic measures [20].
Too many of the subjects here succumbed or had lung
transplantations soon after their last experimental T-cell assays,
without having had additional, interval PFTs, to render these
analyses meaningful. However, 27 study subjects had prior
CD28% determinations, along with concurrent PFTs, as partic-
ipants of an ongoing longitudinal study.
The net change of aggregate CD28% between the preceding
and latest determinations among this subpopulation was
20.4460.53. Ten (10) of these patients had increases of CD28%
(1.760.6) with repeat testing 4.660.6 months later, in contrast to
the other 17 IPF subjects with interval CD28% decrements
(21.760.6) over 4.660.5 months. The FVC declined significantly
less among those subjects with interval CD28% increases
(20.0460.05 L) compared to those with decreasing CD28%
values (20.1560.07 L) (p = 0.05). Moreover, interval changes of
CD28% among individual subjects were also correlated with
corresponding changes of their lung volumes, in terms of both
absolute measures (Figure 4A), and as time-dependent rates
(Figure 4B). Although there were also similar trends for greater
decrements of DLCO and DLCO%p among the subpopulation
with interval decreases of CD28%, these intergroup comparisons
did not reach statistical significance (data not shown).
CD28 Down-Regulation in IPF Patients Is Associated with
Clinical Outcomes
Given that CD28% values have also been shown to associate
with outcome measures in other populations with chronic
immunologic disorders [20–23,32–34], we tested the hypothesis
that these quantitative CD4 T-cell phenotype assays might have
clinical prognostic value for patients with IPF.
The eventual progression of lung dysfunction in IPF patients
almost inevitably results in either lung transplantation or the death
of those afflicted [1]. However, these dichotomous outcomes are
not truly independent events. Lung transplantation ostensibly,
albeit by no means invariably, diminishes or delays deaths of IPF
patients, although the procedure itself is also associated with a
finite inherent mortality [36]. Hence, we initially tallied occur-
rences of either lung transplantations or deaths as equivalent
outcome end-points. Receiver operating characteristic (ROC)
curve analyses indicated that cut-off values for CD28% = 82
seemed to provide the best compromise of optimal specificity (the
most important consideration) and sensitivity for these major,
adverse clinical events.
Those IPF patients having the most extreme CD28 down-
regulation, with CD28% ,82 (henceforth denoted as CD28%
Low), had significantly worse 12-month outcomes than the cohort
with CD28%$82 (CD28% High) (Figure 5A). These intergroup
survival differences were also apparent with six-month analyses
Figure 3. Segregated autologous CD4+CD28+ and CD4+
CD28null cells from peripheral blood of IPF patients (n =9)
had similar proliferations (determined by BrdU incorporation)
in 5-day control (unstimulated) cultures, as well as after
stimulation with plate-bound anti-CD3 monoclonal antibody.
doi:10.1371/journal.pone.0008959.g003
Figure 4. Associations of CD28 expression with pulmonary function. Changes of CD28% with replicate testing (Delta CD28%) were
significantly correlated with concomittant interval changes of A.) absolute FVC (Delta FVC) and B.) FVC as a time-dependent rate (Delta FVC/month).
doi:10.1371/journal.pone.0008959.g004
CD4+CD28null T-Cells in IPF
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(27% vs. 68%, CD28% Low and CD28% High, respectively,
p = 0.004).
Deaths accounted for 24 of the major adverse events, and 20
other subjects had lung transplantations. Seventeen (17) deaths in
the study population were directly attributable to respiratory
failure. One of the CD28% High subjects died from a myocardial
infarction, and another had fatal pulmonary thromboemboli. Five
(5) other deaths (four CD28% High and one CD28% Low
patient), were due to unknown causes in subjects with preexistent
severe pulmonary dysfunction.
To exclude cryptic confounding by potential vagaries of the
transplantation selection process (despite ‘‘double blinding’’
between the clinicians and laboratory investigators), we performed
post hoc actuarial analysis limited to those IPF subjects who did not
have lung transplantations during the year after their T-cell
assays. Despite lesser statistical power due to fewer subjects, the
12-month survival of the CD28% High patients (6866%) was still
significantly greater than that of the CD28% Low cohort
(20618%) (p = 0.007).
CD28% High and CD28% Low cohorts were well matched
with respect to demographic characteristics (Table 1).
CD4+CD28null cells can reportedly accumulate with aging, but
this typically occurs during the eight decade of life or later
[19,25]. Nonetheless, there was no apparent correlation
between age and CD28 expression in the IPF cohort
(rs =20.1, p = 0.36), the overall age distributions of the
comparison populations here were equivalent (Table 1), and
both the number (n = 15) and proportion (19%) of octogenarians
among CD28% High were actually greater than among the
CD28% Low (n = 1 [9%]). Absolute DLCO values were
decreased in the CD28% Low, but there was a less significant
intergroup difference of the DLCO as a percentage of normal
predicted values (DLCO%p) (Table 1).
Figure 5. Associations of CD28% espression with clinical
outcome. A.) Survival curves show cumulative freedom from major
adverse events (lung transplantation or death) of IPF patients. Those
subjects with the most extreme CD28 down-regulation, with CD28
expressed on ,82% of their circulating CD4 T-cells (CD28% Low), had
much worse outcomes than the cohort with greater proportions of
CD4-Tcells that expressed CD28 (CD28% High). Numbers in parenthesis
at the ends of survival curves denote remaining, unafflicted subjects
that were censored at 12 months of observation. B.) Survival curves
showing that cummulative freedom from major adverse events of IPF
patients who have either significant CD28 downregulation (CD28%
Low) or diffusing capacities for carbon monoxide, as percentages of
predicted normal values (DLCO%p) ,38, had worse outcomes than the
IPF cohort who were both CD28% High and had more normal DLCO%p.
doi:10.1371/journal.pone.0008959.g005
Table 1. Subject Characteristics.
(CD28% High) (CD28% Low)
n 78 11
Age (years) 69.661.6 71.762.6
Male –n (%) 55 (71) 8 (73)
Former Smoker –n (%) 56 (72) 8 (73)
Caucasian –n (%) 76 (97) 10 (91)
African-American –n (%) 1 (1) 1 (9)
Native American –n (%) 1 (1) 0
Lung Biopsy- n (%) 48 (62) 7 (64)
CD28% 96.460.5 66.264.0*
FVC (L)
(n)
2.460.1
(62)
2.160.2
(9)
FVC%p
(n)
60.562.4
(62)
57.764.3
(9)
FEV1/FVC
(n)
0.8460.01
(62)
0.8560.01
(9)
DLCO (ml CO/min/mm Hg)
(n)
10.760.7
(50)
6.360.9**
(7)
DLCO%p
(n)
43.662.3
(50)
31.064.7{
(7)
Medications-n (%)
None 56 (72) 9 (82)
Prednisone 6 (8) 1 (9)
IFN-c 2 (3) 0
IFN-c + Prednisone 7 (9) 0
CD28% High denotes those subjects in whom $82% of their circulating CD4 T-
cells co-express CD28. CD28% Low denotes those subjects in whom ,82% of
their circulating CD4 T-cells express CD28. CD28% is defined here as the
proportion of circulating CD4 T-cells that also express CD28. FVC; forced vital
capacity, FVC%p percentage of normal predicted FVC, FEV1/FVC; forced
expiratory volume in 1 second, DLCO; diffusing capacity for carbon monoxide,
DLCO%p; percentage of normal predicted DLCO. One CD28% High biopsy
showed end-stage, honeycombed fibrotic lung, whereas all other histologic
patterns were usual, interstitial pneumonia. *p,0.0001, **p = 0.007; {p,0.045.
doi:10.1371/journal.pone.0008959.t001
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The Prognostic Value of CD28 Measures Is Independent
of Pulmonary Function
We performed further analyses to ensure that the extent of
CD28 expression in these subjects was an independent variable,
relative to PFTs, for clinical outcome prognostications. The odds
ratio (OR) for adverse clinical outcome (death or transplantation)
of IPF patients with CD28% ,82 was 13.0, with 95% confidence
intervals (CI) 1.6-111.1. The inclusion of PFT values, as co-
independent continuous variables in a logistic regression model (in
addition to CD28%), did not enhance associations with adverse
events, with individual OR for FVC, as a percentage of normal
predicted values (FVC%p) = 1.0 (CI: 1.0 to 1.1), and for
DLCO%p = 1.1 (CI: 1-to-1.2).
We hypothesized that the generally reported poor associations
between single, cross-sectional PFT values and prognoses of IPF
patients [37] may possibly be due, at least in part, to potential
confounding effects of CD28 down-regulation. Since the mortality
associated with CD28 down-regulation per se appears to be
independent of concurrent physiologic measures, the unrecog-
nized inclusion of patients with significant proportions of
CD4+CD28null cells in earlier analyses may have confounded
assessments based solely on cross-sectional measures of pulmonary
function (i.e., increase the ‘‘noise to signal ratio’’). Moreover, the
identification of other facile measures that are also predictive of
patient outcomes, in addition to assays of circulating CD4 T-cell
CD28 expressions, could be useful for clinical management,
particularly if these determinations could be applicable to the IPF
subjects who do not have significant CD28 down-regulation.
Accordingly, we examined the prognostic values of PFT
abnormalities in the CD28% High cohort to assess whether this
subpopulation could be further stratified for risks of adverse
clinical outcomes (death or lung transplantation). ROC curve
analyses indicated that values of FVC%p,52 and DLCO%p,38
had the best respective combinations of specificities (the most
important consideration) and sensitivities for adverse clinical
outcomes. Fifty (50) CD28% High IPF patients had complete
pulmonary function tests (both FVC and DLCO measures)
concurrent with their CD4 T-cell assays and were evaluable here.
Twelve-month freedom from adverse outcomes of the CD28%
High patients with FVC%p$52 (n = 33) was 7068%, compared
to 29611% among those with FVC%p,52 (p = 0.001). The
DLCO%p seemed to provide slightly better risk stratification
among the CD28% High patients, with corresponding one-year
freedoms from adverse events of 7668% and 29610% for those
with values above (n = 24) and below (n = 26) the cut-off of 38,
respectively (p = 0.0003).
The potential utility of risk assessments using combinations of
independent prognostic parameters may be indicated by survival
analyses using either CD28% or DLCO%p as outcome indicators.
Thirty-two (32) of the IPF patients studied here had either extreme
CD28% down-regulation (CD28%,82) or DLCO%p values,38.
Of the 11 patients that had CD28 down-regulation (Table 1), six
(6) also had DLCO%p,38, another had a DLCO%p = 54, and
four others did not have DLCO determinations concurrent with
their CD4 assays. A total of 29 IPF patients had both CD28%
$82 and concurrent DLCO%p$38. Twelve-month freedom
from adverse clinical outcomes was 7668% for the latter,
compared to 2267% among those patients with either CD28
down-regulation or DLCO%p,38 (Figure 5B). The OR for the
association between adverse clinical events and the presence of
either CD28%,82 or DLCO%p,38 was 11.2, with 95% CI 3.4–
37.1. The addition of low FVC%p criteria (FVC%p,52) to the
combined low CD28% and/or low DLCO%p values slightly
weakened the association with adverse events (OR: 10.3; CI: 3.0–
34.9). Thus, the presence of either CD28% down-regulation or low
DLCO%p values, as simultaneous, combined, cross-sectional
ascertainments, would seemingly identify a large proportion of
the patients within an IPF cohort who are at greatest risk for
serious adverse events within the next few months.
CD4+CD28null T-Cells Are Present in IPF Lungs
Since the IPF subjects here were scrupulously free of
extrapulmonary pathology or inflammatory foci, we hypothesized
the circulating CD4+CD28null cells of these patients originated in
their diseased lungs. Moreover, the presence of these unusual T-
cells in IPF lungs would further imply the associations of CD28
down-regulation with disease manifestations here (Figures 4 and 5)
may not be merely epiphenomenal. Accordingly, we used confocal
microscopy to examine sections of IPF lungs removed during
therapeutic pulmonary transplantations.
We reasoned that tissue imaging assays based on positive
expressions of specific CD4+CD28null cell characteristics would be
more reliable and preferable to finding that CD28 did not appear
to be present (which could also be due to poor antibody staining).
Granzyme B seemed a useful surrogate marker for this purpose,
since the majority of CD4+CD28null cells produce this cytotoxic
mediator, unlike ‘‘normal’’ CD4+CD28+ T-cells (Figure 1B).
However, since natural killer (NK) cells can also express CD4
and produce cytotoxic mediators, it was necessary to confirm the
intrapulmonary CD4+granzyme B+ cells also co-expressed CD3
(and are thus T-cells).
Confocal microscopy images revealed numerous cells positive
for CD4, CD3 and granzyme B were widely distributed within
alveolar epithelial areas of the IPF lungs, as well as in or proximate
to fibrotic foci of both explant specimens (Figure 6).
Discussion
These data demonstrate that the CD4+CD28null T-cells of IPF
patients exhibit unusual characteristics (Figure 1B and Figure 2)
that are very similar to analogous cells isolated from other patient
populations with chronic immunologic diseases [19–34]. Infiltra-
tions of these unusual CD4+CD28null T-cells were evident in IPF
lungs (Figure 6). Changes of CD4 T-cell CD28 expression with
replicate studies of subjects were directly correlated with
corresponding changes of their lung volumes (Figure 4). Most
importantly, marked CD28 down-regulation on the peripheral
CD4 T-cells of individual IPF patients is associated with a higher
likelihood of their requiring lung transplantations or dying during
the next year (Figure 5A), and these T-cell measures also seem to
complement and enhance the prognostic utility of pulmonary
physiologic testing (Figure 5B).
Nearly all normal CD4 T-lymphocytes express CD28 on their
cell surfaces [38], and finding significant proportions of circulating
CD4+CD28null T-cells is distinctly abnormal [19–34]. In all cases
of which we are aware, possibly excepting the very aged, CD28
down-regulation on significant proportions of peripheral CD4 T-
cells is a specific indicator of an ongoing, chronic inflammatory
response, as previously described in patients with autoimmune
syndromes, persistent inflammation-provoking infections, or other
long-standing immunologic disorders [19–34].
The pathophysiologic importance of the CD28 ‘‘deficiency’’ per
se in these patients is uncertain. Cognate interactions of T-cell
CD28 with ligands (e.g., CD80 and CD86) provide a ‘‘second
signal’’ for lymphocyte activation, in conjunction with the primary
signals mediated by TCR engagements with antigen-MHC
complexes. Nonetheless, neither previously activated (‘‘memory’’)
CD4 nor naı¨ve CD8 T-cells require CD28 for activation, and
CD4+CD28null T-Cells in IPF
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other costimulatory molecules can also provide the second signal
necessary for initial activations of naı¨ve CD4 cells [38,39]. Since
CD28 costimulation is not invariably essential to evoke T-
lymphocyte responses, the absence of this molecule on CD4 T-
cells of patients with immunologic diseases [19–34] is perhaps
most immediately significant in providing a facile marker to
identify the daughter progeny of repeated, antigen-driven
proliferation cycles. However, certain other characteristics of the
CD4+CD28null cells, seen here in greatest proportions among the
IPF patients destined for poor outcomes, may have potential
pathogenic significance.
The overall cytokine production profile of the IPF
CD4+CD28null cells is highly comparable to that previously
observed among analogous lymphocytes derived from distinctly
different patient populations with other chronic immunologic
disorders [20,24]. Thus, it seems most likely that the singular
characteristics and functional modifications of this cell phenotype
are a biologically conserved (and presumably important) compo-
nent of the adaptive immune response to chronic stimulation by
diverse antigen(s). As such, and amongst other possibilities, the
ability to generate CD4+CD28null cells with repeated/chronic
antigen engagements could conceivably represent an evolutionary
adaptation to more effectively counter difficult-to-eradicate
microbial pathogens [19].
Chronic adaptive immune responses in human diseases are
extraordinarily complicated. Antigen-activated T-cells can, in
appropriate circumstances, undergo innumerable divisions, result-
ing in prodigious numbers of clonal daughter progeny, including
variable proportions of CD4+CD28null cells [19]. In turn, these
complex and changing subpopulations of T-cells with evolving
phenotypes and functions produce diverse mediators that also
activate and/or recruit successive waves of other immune effectors
(macrophages, neutrophils, dendritic cells, etc.), as well as
epithelium and many mesenchymal cells. These second- and
third-tier effector cells also add their productions of interrelated,
interactive, and often redundant mediators and other elaborations
in what can become an unfathomably complex inflammatory
conflagration (18).
Accordingly, the exact role(s) the singular functions of
CD4+CD28null could directly contribute to tissue injuries of IPF
(or other chronic immunologic diseases [19–34]) in situ cannot be
deduced from highly reductionist in vitro studies of single isolated
cell types. Nonetheless, it may still be notable that several TH1 and
other pro-inflammatory mediators which initiate or amplify
immune responses (e.g., IL-1b, IL-6, TNF-a, G-CSF) were
comparatively over-produced by the IPF CD4+CD28null cells
relative to their autologous CD4+CD28+ counterparts, both
constitutively, and with TCR stimulation (Figure 2). Moreover,
the perforin and granzyme B productions (Figure 1B) of the
CD4+CD28null lymphocytes could conceivably account for
infiltrates of cytotoxic granule-laden lymphocytes that are present
in IPF lungs [40] (Figure 6), and are believed to contribute to the
pulmonary epithelial apoptosis of this disease [35]. In comparison,
TH2 cytokine productions by the CD4
+CD28null cells were
typically relatively little increased upon TCR stimulation, although
their elaboration of IL-4, a potentially important mediator of
fibrogenesis [41], is a notable exception.
Furthermore, the many pro-injurious mediator productions of
CD4+CD28null cells are also strikingly contrasted with their
relative deficiencies of opposing, counter-regulatory functions that
could potentially limit or modify inflammatory processes. The
comparatively lesser production of IL-10 by CD4+CD28null cells
may have particular biologic importance in fibrotic disorders,
given the possible roles of this cytokine in general suppression of
deleterious immune responses [42] and inhibition of TGF-b-
mediated fibrogenesis [43]. CD28 signaling has been implicated in
the induction of FoxP3 and generation of CD4+CD25+ Tregs [44].
Consequently, lack of this costimulatory function could plausibly
account for the comparative paucity of FoxP3 among the
CD4+CD28null cells, and these findings are also broadly
concordant with recent observations that CD4+FoxP3+ Tregs are
generally diminished among IPF patients (17). The net effects of
the seeming imbalance between pro-injurious and counter-
regulatory (dampening) functions could conceivably result in
promotion of more injurious responses with serial (chronic) antigen
engagements (including intrapulmonary antigens [13]) by T-
Figure 6. Localization of CD4, CD3, and granzyme B expressing cells in IPF lungs. A.) and B.) Cells expressing CD4 (Green) and granzyme B
(red), respectively, are widely distributed in IPF lung sections. C.) DAPI (blue) stains DNA within cell nuclei. D.) Co-localizations of CD4 and granzyme B
(yellow) among nucleated cells are seen in the merged image. Nearly all the intrapulmonary CD4+ cells co-expressed granzyme B. Images E.), F.) and
G.) similarly depict CD4 (green), CD3 (red) and DAPI (blue). H.)Merged image shows most of the CD4+ cells also co-expressed CD3. Similar results were
present in both IPF lungs. The majority of CD4+ cells in these IPF lung sections co-expressed both granzyme B and CD3 and are, thus, CD4+CD28null T-
cells (see also Figure 1B). All images are 60x.
doi:10.1371/journal.pone.0008959.g006
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lymphocyte populations that have increased proportions of
CD4+CD28null cells.
Because of the downstream amplification of T-cell effector
responses [18], and extraordinary numbers of T-cells in an
individual, antigen activation of even a limited fraction of total
lymphocytes can have far-reaching effects. The proportion of
peripheral CD4+CD28null cells among the CD28% Low subjects
here was ,34% (Table 1). Since the circulating T-cell compart-
ment represents only a miniscule fraction of the lymphocytes that
traffic from inflamed tissue and proximate lymph nodes [45,46],
the total numbers of these highly altered lymphocytes in the IPF
patients is incalculably large. By comparison, the precursor
frequency for T-cells reactive to conventional peptide antigens
(e.g., influenza epitopes) is estimated at 1:1000 to 1:10,000 [47].
Microbial superantigens are among the most potent antigens
known, can mediate life-threatening toxic shock syndrome, and
activate ,2 20% of total T-cells among infected individuals [48].
Alloantigens are often highly immunogenic, capable of evoking
brisk, severe, and refractory allograft rejection, and are initially
recognized by #10% of the recipient T-cell repertoire [49].
Daughter progeny of T-cell clonal proliferations (which can
develop into CD4+CD28null cells [19]) comprise a very similar
proportion of circulating CD4 T-cells (,36%) among lung
transplant recipients with severe lung damage due to obliterative
bronchiolitis [50]. The frequency of CD4+CD28null cells among
the IPF patients destined for poor outcomes here are also highly
comparable to the proportions of these cells among lung transplant
recipients with chronic rejection who had similarly guarded
prognoses [20], and is even greater than in many other disease
conditions wherein these particular lymphocytes have been
implicated in pathogenesis [21–34]. Thus, the CD4+CD28null
cells among many of the IPF patients here appear at least
numerous enough to be potentially capable of causing or
contributing to disease manifestations.
We do not believe the present data justify use of CD28 assays,
either alone or in combinations with PFTs (e.g., DLCO%p), as a
definitive clinical tool in IPF patients yet, pending additional and
confirmatory study. This initial, cross-sectional, exploratory
examination was focused on investigating potential immunopath-
ogenic phenomena of IPF per se and, as such, we intentionally
excluded subjects with infections, malignancies, accelerated IPF,
or co-morbid autoimmune disorders that could, perhaps, con-
found the operating characteristics of these T-cell assays in actual
patient management. Prospective serial observations in a large
patient cohort will more accurately define the accuracy and
validity of CD4 T-cell assays for clinical prognostications, and a
longitudinal trial is currently in progress.
In summary, the present data show that the extent of CD28
expression on circulating CD4 T-cells of IPF patients is associated
with disease outcomes. Among other implications, these findings
are further evidence for a role of adaptive immune processes in the
pathogenesis of IPF [3–15,17]. The intrapulmonary antigen(s) that
drives T-cell proliferation [13], and the eventual generation of
CD4+CD28null lymphocytes in these patients, has not yet been
identified, and possibilities remain broad, including an exogenous
protein(s) or hapten, persistent microbes, or even a self-epitope
[3–7,13]. The findings here may illuminate a novel paradigm of
IPF progression that could ultimately lead to more effective
counters for this devastating disease, possibly including selective
targeting of singularly pathogenic lymphocyte subpopulations. If
further substantiated, moreover, the practical value of simple,
minimally invasive T-cell assays that identify patients destined for
disease progression would be considerable. Thus, heightened
surveillance and/or earlier interventions (e.g., lung transplanta-
tions or experimental therapies) could be directed to those patients
at greatest immediate risk, while possibly obviating morbid
treatments in those destined for more indolent courses.
Materials and Methods
Subjects, Assignments of Diagnoses, and Treatment
Decisions
IPF patients were recruited from referrals to the interstitial lung
disease (ILD) clinic at the University of Pittsburgh. Normal
controls were recruited by solicitation, and did not have any
known systemic or immunologic disorders that affect CD28
expression [19]. All subjects gave written informed consent per the
University of Pittsburgh Investigational Review Board (IRB).
IPF diagnoses were prospectively established by expert,
specialized ILD clinicians who analyzed all available information,
including medical histories and physical exams, PFTs, laboratory
studies that included serologic tests for autoimmune syndromes,
chest radiographs and computerized tomography scans, and
histologic evaluations of lung biopsies and pulmonary explants
surgically removed during transplantations. All IPF subjects who
provided blood or tissue specimens here fulfilled consensus
diagnostic criteria [1]. None had ongoing acute exacerbations of
IPF [3], clinical or serologic evidence of autoimmune disorders,
malignancies, or concurrent infections. Subjects were also
excluded if they had histologic patterns on lung biopsy (or explant)
other than usual interstitial pneumonia (UIP) or, in one case, end-
stage fibrotic lung disease with honeycombing [51].
The clinicians caring for these patients were blinded to the
results of these experimental T-cell studies. Conversely, the T-cell
assay results were analyzed by laboratory-based investigators
blinded to subject identities, disease manifestations, and clinical
outcomes.
Cell Preparations and Flow Cytometry
Mononuclear cells were isolated from peripheral blood of study
subjects by density gradient centrifugation for use in flow
cytometry or functional assays. PBMNC for cell surface charac-
terizations were incubated with monoclonal antibodies (MAb)
immediately after their isolation, and then promptly analyzed by
flow cytometry. Unless otherwise denoted, MAb, including isotype
control antibodies, were purchased from BD Pharmingen (San
Diego, CA). These MAb included CD4 (RPA-T4), CD28
(CD28.2), CD8 (HIT8a), MHC Class II (DR) (L243), CD25 (M-
A251), granzyme B (GB11), and perforin (dG9). Anti-FoxP3 MAb
(FJK-16S) was purchased from eBioscience, San Diego, CA.
Quantitations were performed on $10,000 live cells and
analyzed using a BD FACSCalibur (BD Bioscience, San Jose,
CA). This instrument has 488 nm and 635 nm lasers, and employs
long pass, short pass, and bandwith filters that transmit
wavelengths 530/30 nm (FL1), 585/42 nm (FL2), 670 nm (FL3),
and 661/16 nm (FL4). Flow cytometry gates were set using control
fluorochrome positive and negative PBMNC (including isotype
controls).
CD28 and other phenotypic markers were quantitated within
respective CD4+CD28+ and CD4+CD28null cell subpopulations, as
detailed elsewhere [20]. In brief, PBMNC were stained with anti-
human CD4-allophycocyanin (APC) and anti-human CD28-
fluorescein isothiocyanate (FITC) MAb, and individual aliquots
of these were also stained with phycoerythrin (PE)-conjugated
MAb against other cell surface epitopes of interest (e.g., HLA-DR,
CD25, etc.). CD4bright cells corresponding to the CD4 T-cell
subpopulation were selectively gated (from within the live cell gate)
for further characterizations (Figures 7A, 7B) [20,52]. CD28 and
CD4+CD28null T-Cells in IPF
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other phenotypic markers were quantitated within respective
CD4+CD28+ and CD4+CD28null subpopulations (Figure 7C).
Intracellular mediators (perforin, granzyme B, and FoxP3) were
also quantitated among freshly isolated PBMNC aliquots that had
been identically stained with anti-human CD4 and CD28 MAb,
and then fixed and permeabilized prior to incubation with MAb
having specificities for the intracellular molecules, per manufac-
turers’ protocols.
The CD28% value for individual patients was defined as the
proportion of their circulating CD4 T-cells that co-express CD28
[20]. Based on prior observations, we anticipated that study of
CD4 T-cell phenotypic markers (e.g., MHC Class II, CD25, etc.)
in 24 IPF subjects would provide very high power to detect
intergroup differences, if their cellular characteristics resembled
those of other patient populations [20]. Specimens for the T-
cell phenotype studies were selected randomly, without prior
knowledge of the corresponding CD28% or subject’s clinical
characteristics.
Cytokine Assays
CD4 T-cells cells for cytokine and proliferative assays were
isolated from PBMNC by negative selection with immunomag-
netic beads (Miltenyi Biotech, Auburn, CA). CD28null cells and
CD28+ cells were segregated from among this CD4 T-cell
population by staining with anti-CD28-phycoerythrin (PE),
followed by positive selection of the latter with anti-PE
immunomagnetic beads (Miltenyi Biotech) [20].
16105 CD4 T-cells (autologous CD28+ and CD28null) were
separately cultured for two days in 96 well plates in both
stimulated (10 mg/ml plate-bound anti-CD3 MAb [OKT3]) and
un-stimulated (basal) conditions. Culture supernatants were
analyzed for cytokine productions using a Bio-PlexTM protein
suspended bead array platform (Bio-Rad, Hercules, CA),
following the manufacturer’s protocols. Prior observations
indicated that study of six (6), randomly-selected specimens
would enable detections of intergroup cytokine production
differences, if characteristics of the IPF CD4 T-cell subpopula-
tions were similar to those seen with cells isolated from another
patient group [20].
CD4 T-Cell Proliferation Assays
These methods have been described elsewhere [20]. In brief,
segregated autologous CD28+ and CD28null CD4 T-cell subpop-
ulations, isolated by immunomagnetic beads, were individually
cultured in duplicate conditions, including unmanipulated (con-
trol) incubations, and in wells previously coated with anti-CD3
MAb (see above). Autologous nurse cells, positively selected from
PBMNC during the initial CD4 T-cell isolations, were added in a
3:1 nurse cell:CD4 T-cell ratio. All CD4+ cells were depleted from
the nurse cells, prior to their use in cultures (%1% residual), by
positive selection with anti-CD4-coated magnetic beads (Invitro-
gen, Carlsbad, CA).
Proliferation within the respective CD4 subpopulations were
measured by bromodeoxyuridine (BrdU) incorporation, using
reagents and methods supplied in a kit (BD Pharmingen). BrdU in
a final concentration of 10 uM was added to cultures 2 days prior
to their harvests. After 561 days of culture, cells were harvested
from wells and stained with anti-CD4 MAb, fixed and permea-
bilized, and then incubated with anti-BrdU and 7-amino-
actinomycin (7-AAD). The proportion of proliferating CD4+ T-
cells (BrdU+) among the viable cells ($diploid DNA content) was
determined by flow cytometry.
Lung Immunostaining
Explanted lung tissues from two IPF patients who underwent
pulmonary transplantations were obtained from the University of
Pittsburgh Health Sciences Tissue Bank. These tissues had been
embedded in optimal cutting temperature (OCT) media immedi-
ately after explantation and stored frozen at 280uC. Lung tissues
were cut into 4 micron thickness using a cryostat, and placed on
slides kept at 280uC until used. These frozen sections were fixed
using 2% paraformaldehyde for 20 minutes. Cell permeabilisation
was carried out by using 0.1% Triton X-100 in phosphate buffered
saline (PBS) for 15 minutes. Sections were rehydrated by three
cycles of incubation for five minutes each in PBS, followed by
washing with 0.5% bovine serum albumin (BSA) in PBS. The
slides were then blocked with 5% donkey serum (Sigma-Aldrich,
St. Louis, MO) in PBS containing 3% BSA for 45 minutes. Slides
were incubated overnight at 4uC in blocking solution supplement-
Figure 7. Flow cytometry methodology (see also references 20, 52). Aliquots of fresh, live peripheral blood mononuclear cells (PBMNC) were
stained with anti-CD4-allophycocyanin (APC), anti-CD28-fluorescein isothiocyanate (FITC), and phycoerythrin (PE)-conjugated antibodies against
other cell epitopes. A.) Ten thousand (10,000) or more live cells were selected for further study, based their side scatter (SSC) and forward scatter (FSC)
characteristics (G1). B.) The brightly staining CD4 cells among these also expressed CD3 (Cy-Chrome) and, thus, are T-cells [52]. C.) These CD4 T-cells
were further characterized based on their expression of CD28. The proportions of CD4+CD28+ T-cells among the total CD4+ T-cell population (upper
left and upper right quadrants) defines the CD28%. The respective proportions of CD4+CD28+ and CD4+CD28null cells that co-expressed other cell
determinants of interest (in this case MHC Class II [DR]) were quantitated. Numbers within the delineated region/quadrants denote the proportions of
cells with these respective characteristics.
doi:10.1371/journal.pone.0008959.g007
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ed with rabbit polyclonal anti-human CD3 (ab5690, Abcam,
Cambridge, MA), and mouse anti-human CD4 MAb (SK3, BD
Biosciences). Separate sections were similarly prepared with rabbit
polyclonal anti-human granzyme B (ab4059, Abcam) and SK3
MAb. Sections were washed 5 times with 0.5% BSA in PBS to
remove unbound primary antibodies, and then incubated with
Alexia 568-conjugated goat anti-rabbit and Alexia 488-conjugated
goat anti-mouse secondary antibodies (both from Invitrogen) for
one hour at 28uC. All primary and secondary antibodies were used
at 1:100 dilutions. Subsequently, the slides were washed five times
with 0.5% BSA in PBS, followed by five washes with PBS alone,
with each wash lasting for five minutes. Cell nuclei were
counterstained with 49,6-diamidino-2-phenylindole (DAPI) (Vec-
tor Lab, Burlingame, CA) for one minute and briefly washed two
times in PBS. Slides were then cleaned and cover slips were
mounted using Gelvatol media obtained from the Center of
Biological Imaging at the University of Pittsburgh. The slides were
dried overnight at 4uC while protected from light, and images
were visualized using an Fluorview 1000TM confocal microscope
(Olympus, Center Valley, PA). Digital image data were archived
and prepared for publication using Adobe Photoshop software
(Adobe Systems Inc., Mountain View, CA).
Statistical Analyses
Intergroup comparisons of continuous data were analyzed by
Mann-Whitney rank-sum tests. Dichotomous variables were
analyzed by Chi-square. Correlations between continuous vari-
ables were established by Spearman rank order. Survival analyses
were performed using product-limit estimation, with comparisons
by Log-rank (Mantel-Cox). Odds ratios and confidence intervals
were established by logistic regression. Data were analyzed using
StatViewTM (SAS, Cary, NC.) Receiver operator characteristic
(ROC) analyses were examined using Analyse-itTM v 2.12
(Analyse-it Software, Ltd, Leeds, UK). Significance was defined
as p,0.05. Data are depicted as mean 6 SEM.
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